Consensus $7.98. The company said, “Gilead (GILD) does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Kymera is expected to reduce Gilead’s GAAP and non-GAAP 2025 EPS by approximately $0.02 – $0.03.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead, Kymera enter license agreement for molecular glue degrader program
- Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says
- Citi views Yeztugo as ‘key growth driver’ for Gilead
- Oppenheimer sees limited near-term impact from Gilead HIV approval
- BMO says lenacapavir approval for prevention a ‘major win’ for Gilead